Questions about cancer? Freephone 1800 200 700 Irish Cancer Society Nurseline

About this trial

This study is designed to assess the safety, overall tolerability, and antiviral activity of “short course” BCV therapy, as compared with current standard of care (SoC), for the treatment of adenovirus (AdV) infections in high-risk (i.e., T cell depleted) pediatric allogeneic hematopoietic cell transplant (HCT) recipients. A virologic response-driven approach to the duration of treatment will be evaluated, in which subjects randomized to BCV therapy are treated until AdV viremia is confirmed as undetectable or until a maximum of 16 weeks of therapy, whichever occurs first.

Patient Profile

2 Months to 17 Years

Where’s this trial being run?

Crumlin Children’s Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: Chimerix ADAPT
Number: 18-22
Full Title:

An Open-label, Randomised, Multi-centre, Parallel Group, Two-arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir versus Standard of Care for Treatment of Adenovirus Infections in High-risk Paediatric Allogeneic Haematopoietic Cell Transplant Recipients.

Principal Investigator: Dr Andrea Malone
Type: Industry Sponsored
Sponsor:

Chimerix

Recruitment Started: Global: Dec 2017
Ireland: 2018
Global Recruitment Target: 141
Ireland Recruitment Target: Not Available